Pharmacological strategies to improve the adherence to highly active antiretroviral therapy
Main Article Content
Keywords
Antiretroviral therapy Highly active
Abstract
Background: adherence to antiretroviral therapy is an important factor in achieving human immunodeficiency virus suppression. The aim was to apply a pharmacological strategy, based in pharmacokinetics measures for improvement the adherence to antiretroviral therapy.
Methods: it was done a descriptive study during eight months, in 75 human immunodeficiency virus positive patients with clinical and social criteria for highly active antiretroviral therapy in Opuwo, Namibia. Pharmacological aspects such as major side effects and dangerous drug-drug interactions were evaluated. Descriptive statistics analysis was applied.
Results: three minor side effects were detected (two for efavirenz and one for nevirapine), and one major side effect for stavudine/lamivudine. Dangerous drug interactions were avoided doing pharmacokinetics measures with efavirenz, stavudine/lamivudine and zidovudine; and between nevirapine and fluconazol or ketoconazol.
Conclusions: the adherence to highly active antiretroviral therapy was improvement with the application of the proposal pharmacological strategy to avoid side effects and dangerous drug interactions.
References
Adherence. En: Training on the use of the Namibian guidelines for antiretroviral therapy. 2005 (Section 1-1).
World Health Organization. Interim WHO clinical staging of HIV/AIDS case definitions for Surveillance. African Region. Geneva: WHO; 2006.
Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13(9):1099-107.
World Health Organization-UNAIDS. Key elements in HIV care and support. Geneva: WHO-UNAIDS; 2000. Texto libre en http://pdf.usaid.gov/pdf_docs/PNACM629.pdf
Principles of art. Resistance and adherence. En: Training on the use of the Namibian guidelines for antiretroviral therapy. 2005 (Unit 3):35.
Ministry of Health and Social Services. Guidelines for anti-retroviral therapy in Namibia. Windhoek, Namibia: CDC; 2005.
Antiretroviral therapy. Patient counseling information. Ministry of Health and Social Services: Pharmaceutical Services; 2005. p. 27-32.
Ministry of Health and Social Services. ARV NEMList drugs interactions. Windhoek, Namibia: Ministry of Health and Social Services; 2004. p. 1-2.
British Medical Association, Royal Pharmaceutical Society of Great Britain. Appendix 1. En: British National Formulary. London: British Medical Association; 2005. p. 716.
Infomed. Formulario nacional de medicamentos. Segunda edición. Cuba: Editorial de Ciencias Médicas; 2006. p. 163-70.
Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84.
Commeyras Ch, Rey JL, Badre-Sentenac S, Essomba-Ntsama C. Determining factors of observance of antiretroviral treatments in Cameroon during the start-up period (2000-2002). Pharmacy Pract. 2006;4(3):117-22. Texto libre en http://redalyc.uaemex.mx/src/inicio/ArtPdfRed.jsp?iCve=69040303
Rodríguez TG, Iranzu AM, Berrocal JM, Gómez-Serranillo R. Adherencia al tratamiento antirretroviral: repercusión del número de tomas diarias. Rev Cubana Farm [Internet]. 2009;43(1). Disponible en: http://www.bvs.sld.cu/revistas/far/vol43_1_09/far08109.htm
Sierra-Madero JG, Franco-San Sebastián D. Tratamiento antiviral en el manejo de la infección por VIH. ¿En dónde estamos y hacia dónde vamos? Rev Invest Clin. 2004;56(2):222-31.
Tornero-Estébanez C, Soria AC, Bonmatí AN, Soler EC, Segura SR. Gasto farmacéutico en medicación antirretroviral y posibilidades de optimización. An Med Intern. 2005;22(12):575-8.
Santos-Corraliza E, Fuertes-Martín A. Efectos adversos de los fármacos antirretrovirales: fisiopatología, manifestaciones clínicas y tratamiento. An Med Intern. 2006;23(7):338-44.